Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Recruiting

Phase 1

Phase 2

LumbrokinaseLumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Sponsor:

Icahn School of Medicine at Mount Sinai

Code:

NCT06511050

Conditions

Long Covid

Post-treatment Lyme Disease Syndrome

Chronic Fatigue Syndrome

Myalgic Encephalomyelitis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Lumbrokinase

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-04. This information was provided to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai on 2024-11-08.